Evolving trends in Streptococcus pneumoniae resistance: Implications for therapy of community-acquired bacterial pneumonia

International Journal of Antimicrobial Agents

Volumn 36, Issue 3, 2010, Pages 197-204

  Jones, Ronald N ^a   Jacobs, Michael R ^b   Sader, Helio S ^a  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Antimicrobial therapy; Community acquired pneumonia; Streptococcus pneumoniae

Indexed keywords

BETA LACTAM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAROLINE; CEFTOBIPROLE; CEFTRIAXONE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; LEVOFLOXACIN; PENICILLIN BINDING PROTEIN; PENICILLIN G; PNEUMOCOCCUS VACCINE; RNA 23S; TELITHROMYCIN; TIGECYCLINE;

ANTIBIOTIC SENSITIVITY; BACTERIAL PNEUMONIA; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; GENE MUTATION; HUMAN; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EVOLUTION; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; SHORT SURVEY; STREPTOCOCCUS PNEUMONIAE; TREATMENT PLANNING; ANTIBIOTIC RESISTANCE; COMMUNITY-ACQUIRED INFECTIONS; DRUG EFFECTS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PNEUMONIA, PNEUMOCOCCAL;

COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

EID: 77954956141     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.04.013     Document Type: Short Survey

References (79)

1. Bartlett J.G., Mundy L.M. Community-acquired pneumonia. N Engl J Med 1995, 333:1618-1624.
2. Jacobs M.R. Antimicrobial-resistant Streptococcus pneumoniae: trends and management. Expert Rev Anti Infect Ther 2008, 6:619-635.
3. National Center for Health Statistics. Health, United States; 2008, with special feature on health of young adults. [accessed 1 May 2009]. http://www.cdc.gov/nchs/data/hus/hus08.pdf.
4. Kollef M.H., Shorr A., Tabak Y.P., Gupta V., Liu L.Z., Johannes R.S. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005, 128:3854-3862. [Erratum in: Chest 2006;129:831].
5. Mandell L.A., Wunderink R.G., Anzueto A. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl. 2):S27-S72. Infectious Diseases Society of America; American Thoracic Society.
6. US Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report: Emerging Infections Program Network, Streptococcus pneumoniae, 2007. Atlanta, GA: CDC; 2008. [accessed 14 May 2010]. http://www.cdc.gov/abcs/reports-findings/survreports/spneu07.pdf.
7. Jacobs M.R. Streptococcus pneumoniae: epidemiology and patterns of resistance. Am J Med 2004, 117(Suppl. 3A):3S-15S.
8. Fine M.J., Smith M.A., Carson C.A., Mutha S.S., Sankey S.S., Weissfeld L.A., et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 1996, 275:134-141.
9. Feikin D.R., Schuchat A., Kolczak M., Barrett N.L., Harrison L.H., Lefkowitz L., et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000, 90:223-229.
10. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902. Hib and Pneumococcal Global Burden of Disease Study Team.
11. Rodriguez A., Lisboa T., Blot S., Martin-Loeches I., Solé-Violan J., De Mendoza D., et al. Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Med 2009, 35:430-438. Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators.
12. De Graeve D., Beutels P. Economic aspects of pneumococcal pneumonia: a review of the literature. Pharmacoeconomics 2004, 22:719-740.
13. Sun H.K., Nicolau D.P., Kuti J.L. Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae. Chest 2006, 130:807-814.
14. Agency for Healthcare Research and Quality. Improving treatment decisions for patients with community-acquired pneumonia. Rockville, MD: AHRQ; 2002. [accessed 15 May 2009]. http://www.ahrq.gov/clinic/pneumonia/pneumonia.htm.
15. Daneman N., Low D.E., McGeer A., Green K.A., Fisman D.N. At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia. Clin Infect Dis 2008, 46:1131-1138.
16. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368:1495-1502.
17. Park I.H., Pritchard D.G., Cartee R., Brandao A., Brandileone M.C.C., Nahm M.H. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 2007, 45:1225-1233.
18. Park I.H., Park S., Hollingshead S.K., Nahm M.H. Genetic basis for the new pneumococcal serotype, 6C. Infect Immun 2007, 75:4482-4489.
19. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI; 2010.
20. Weinstein M.P., Klugman K.P., Jones R.N. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 2009, 48:1596-1600.
21. Jacobs M.R., Bajaksouzian S., Windau A., Good C., Biek D., Critchley I.A., et al. Activity of ceftaroline against emerging serotypes of Streptococcus pneumoniae. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 12-14 September 2009, San Francisco, CA 2009, ASM Press, Washington, DC.
22. Lynch J.P., Zhanel G.G. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy. Semin Respir Crit Care Med 2005, 26:575-616.
23. Widdowson C.A., Klugman K.P. Molecular mechanisms of resistance to commonly used non-β-lactam drugs in Streptococcus pneumoniae. Semin Respir Infect 1999, 14:255-268.
24. Davies T.A., Shang W., Bush K. Activities of ceftobiprole and other β-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrob Agents Chemother 2006, 50:2530-2532.
25. Hakenbeck R., Kaminski K., König A., van der Linden M., Paik J., Reichmann P., et al. Penicillin-binding proteins in β-lactam-resistant Streptococcus pneumoniae. Microb Drug Resist 1999, 5:91-99.
26. Deeks S.L., Palacio R., Ruvinsky R., Kertesz D.A., Hortal M., Rossi A., et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. Pediatrics 1999, 103:409-413. The Streptococcus pneumoniae Working Group.
27. Pallares R., Liňares J., Vadillo M., Cabellos C., Manresa F., Viladrich P.F., et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995, 333:474-480.
28. Pallares R., Capdevila O., Liňares J., Grau I., Onaga H., Tubau F., et al. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. Am J Med 2002, 113:120-126.
29. Yu V.L., Chiou C.C., Feldman C., Ortqvist A., Rello J., Morris A.J., et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003, 37:230-237. International Pneumococcal Study Group.
30. Farrell D.J., Couturier C., Hryniewicz W. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003-2004). Int J Antimicrob Agents 2008, 31:245-249.
31. Jenkins S.G., Brown S.D., Farrell D.J. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob 2008, 7:1.
32. Janoir C., Zeller V., Kitzis M.D., Moreau N.J., Gutmann L. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother 1996, 40:2760-2764.
33. Pletz M., McGee L., Jorgensen J., Beall B., Facklam R.R., Whitney C.G., et al. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother 2004, 48:3491-3497. Active Bacterial Care Surveillance Team.
34. Jacobs M.R., Koornhof H.J., Robins-Browne R.M., Stevenson C.M., Vermaak Z.A., Freiman I., et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978, 299:735-740.
35. Doern G.V., Brueggemann A., Holley H.P., Rauch A.M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996, 40:1208-1213.
36. Richter S.S., Heilmann K.P., Dohrn C.L., Riahi F., Beekmann S.E., Doern G.V. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 2009, 48:e23-e33.
37. Van Bambeke F., Reinert R.R., Appelbaum P.C., Tulkens P.M., Peetermans W.E. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs 2007, 67:2355-2382.
38. Dagan R., Klugman K.P. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 2008, 8:785-795.
39. Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction: eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008;57:144-8.
40. Shields B. Prevnar (heptavalent pneumococcal conjugate vaccine): disease prevention in infants and children. J Pediatr Health Care 2001, 15:203-210.
41. Brueggemann A.B., Pai R., Crook D.W., Beall B. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog 2007, 3:e168.
42. Gertz R.E., Li Z., Pimenta F.C., Jackson D., Juni B.A., Lynfield R., et al. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J Infect Dis 2010, 201:770-775. Active Bacterial Care Surveillance Team.
43. Mera R., Miller L.A., Fritsche T.R., Jones R.N. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist 2008, 14:101-107.
44. Jacobs M.R., Bajaksouzian S., Bonomo R.A., Good C.E., Windau A.R., Hujer A.M., et al. Occurrence, distribution, and origins of Streptococcus pneumoniae serotype 6C, a recently recognized serotype. J Clin Microbiol 2009, 47:64-72.
45. Nahm M.H., Lin J., Finkelstein J.A., Pelton S.I. Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J Infect Dis 2009, 199:320-325.
46. Critchley I.A., Jacobs M.R., Brown S.D., Traczewski M.M., Tillotson G.S., Janjic N. Prevalence of serotype 19A Streptococcus pneumoniae among isolates from US children in 2005-2006 and activity of faropenem. Antimicrob Agents Chemother 2008, 52:2639-2643.
47. Jacobs M.R., Good C.E., Bajaksouzian S., Windau A.R. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin Infect Dis 2008, 47:1388-1395.
48. Messina A.F., Katz-Gaynor K., Barton T., Ahmad N., Ghaffar F., Rasko D., et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J 2007, 26:461-467.
49. Reynolds T.A. Update on emerging infections: news from the Centers for Disease Control and Prevention. Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae-Massachusetts, 2001-2006. Ann Emerg Med 2008, 51:312-315.
50. Moore M.R., Gertz R.E., Woodbury R.L., Barkocy-Gallagher G.A., Schaffner W., Lexau C., et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008, 197:1016-1027.
51. Jacobs M.R., Felmingham D., Appelbaum P.C., Grüneberg R.N. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003, 52:229-246. Alexander Project Group.
52. Castanheira M., Gales A.C., Pignatari A.C.C., Jones R.N., Sader H.S. Changing antimicrobial susceptibility patterns among Streptococcus pneumoniae and Haemophilus influenzae from Brazil: report from the SENTRY antimicrobial surveillance program (1998-2004). Microb Drug Resist 2006, 12:91-98.
53. Deshpande L.M., Sader H.S., Debbia E., Nicoletti G., Fadda G., Jones R.N. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004). Diagn Microbiol Infect Dis 2006, 54:157-164.
54. Fluit A.C., Schmitz F.J., Jones M.E., Acar J., Gupta R., Verhoef J., et al. Antimicrobial resistance among community-acquired pneumonia isolates in Europe: first results from the SENTRY Antimicrobial Surveillance Program 1997. Int J Infect Dis 1999, 3:153-156. SENTRY Participants Group.
55. Johnson D.M., Stilwell M.G., Fritsche T.R., Jones R.N. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Diagn Microbiol Infect Dis 2006, 56:69-74.
56. Ishida T., Maniwa K., Kagioka H., Hirabayashi M., Onaru K., Tomioka H., et al. Antimicrobial susceptibilities of Streptococcus pneumoniae isolated from adult patients with community-acquired pneumonia in Japan. Respirology 2008, 13:240-246.
57. Song J.H., Oh W.S., Kang C.I., Chung D.R., Peck K.R., Ko K.S., et al. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian Network for Surveillance of Resistant Pathogens. Int J Antimicrob Agents 2008, 31:107-114. Asian Network for Surveillance of Resistant Pathogens Study Group.
58. European Antimicrobial Resistance Surveillance System. EARSS Annual Report 2008. Bilthoven, The Netherlands: National Institute for Public Health and the Environment; 2009.
59. van de Sande-Bruinsma N., Grundmann H., Verloo D., Tiemersma E., Monen J., Goossens H., et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008, 14:1722-1730. European Antimicrobial Consumption Projects Group.
60. Jacobs M.R., Good C.E., Beall B., Bajaksouzian S., Windau A.R., Whitney C.G. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. J Clin Microbiol 2008, 46:982-990.
61. Jacobs M.R., Good C.E., Windau A.R., Bajaksouzian S., Biek D., Critchley I.A., et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the USA. Antimicrob Agents Chemother 2010, 54:2716-2719.
62. European Committee on Antimicrobial Susceptibility Testing. EUCAST; 2009. [accessed 14 May 2010]. http://www.eucast.org/clinical_breakpoints/.
63. Lim W.S., Baudouin S.V., George R.C., Hill A.T., Jamieson C., Le Jeune I., et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009, 64(Suppl. 3):iii1-iii55.
64. Weiss K., Low D.E., Cortes L., Beaupre A., Gauthier R., Gregoire P., et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004, 11:589-593.
65. Blasi F., Farrell D.J., Dubreuil L. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study year 5 (2003-2004). Diagn Microbiol Infect Dis 2009, 63:302-308.
66. Fogarty C.M., Patel T.C., Dunbar L.M., Leroy B.P. Efficacy and safety of telithromycin 800mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study. BMC Infect Dis 2005, 5:43-51.
67. Fogarty C.M., Kohno S., Buchanan P., Aubier M., Baz M. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin. J Antimicrob Chemother 2003, 51:947-955.
68. Clay K.D., Hanson J.S., Pope S.D., Rissmiller R.W., Purdum P.P., Banks P.M. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006, 144:415-420.
69. Fritsche T.R., Sader H.S., Jones R.N. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn Microbiol Infect Dis 2008, 61:86-95.
70. Fenoll A., Aguilar L., Robledo O., Giménez M.J., Granizo J.J., Biek D., et al. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob Agents Chemother 2008, 52:4209-4210.
71. Ge Y., Biek D., Talbot G.H., Sahm D.F. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008, 52:3398-3407.
72. McGee L., Biek D., Ge Y., Klugman M., du Plessis M., Smith A.M., et al. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2009, 53:552-556.
73. Morrissey I., Ge Y., Janes R. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Int J Antimicrob Agents 2009, 33:515-519.
74. Patel S.N., Pillai D.R., Pong-Porter S., McGeer A., Green K., Low D.E. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008. J Antimicrob Chemother 2009, 64:659-660.
75. Panagiotidis G., Bäckström T., Asker-Hagelberg C., Jandourek A., Weintraub A., Nord C.E. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother 2010, 54:1811-1814.
76. McKeage K., Keating G.M. Tigecycline: in community-acquired pneumonia. Drugs 2008, 68:2633-2644.
77. Bergallo C., Jasovich A., Teglia O., Oliva M.E., Lentnek A., de Wouters L., et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009, 63:52-61. 308 Study Group.
78. Dartois N., Castaing N., Gandjini H., Cooper A. Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience. J Chemother 2008, 20(Suppl. 1):28-35. Tigecycline 313 Study Group.
79. Tanaseanu C., Bergallo C., Teglia O., Jasovich A., Oliva M.E., Dukart G., et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008, 61:329-338. 308 and 313 Study Groups.